L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.72 NOK -2.39%
Market Cap: 293.3m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-2.6
Current
-3.9
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.6
=
Enterprise Value
250m NOK
/
EBITDA
-95.8m NOK
All Countries
Close
Market Cap EV/EBITDA
NO
Lytix Biopharma AS
OSE:LYTIX
300.5m NOK -2.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -222 040.8
US
Abbvie Inc
NYSE:ABBV
315.4B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
142B USD 16.1
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 9.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD 21.9
US
Epizyme Inc
F:EPE
94.1B EUR -508.9
AU
CSL Ltd
ASX:CSL
139B AUD 20.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 15.8
US
Seagen Inc
F:SGT
39.3B EUR -58.1
NL
argenx SE
XBRU:ARGX
38.2B EUR -165.9
EBITDA Growth EV/EBITDA to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBITDA: 16.5
Negative Multiple: -2.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 040.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.1
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.9 N/A N/A
AU
CSL Ltd
ASX:CSL
20.2
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -165.9 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.9
2-Years Forward
EV/EBITDA
-17.2
3-Years Forward
EV/EBITDA
N/A